Literature DB >> 20694515

A purging procedure for pantoprazole and 4-lumen catheters to prevent IV drug incompatibilities.

Thilo Bertsche1, Carolin Veith, Alexander Stahl, Torsten Hoppe-Tichy, F Joachim Meyer, Hugo A Katus, Walter E Haefeli.   

Abstract

OBJECTIVE OF THE STUDY: The purpose of this prospective intervention study was to assess the number of patients with Y-site incompatibilities before and after implementation of quality improvement measures to prevent incompatibilities consisting of a focused instruction for pantoprazole as a drug frequently involved in incompatible drug pairs and of a recommendation to use 4-lumen instead of 3-lumen catheters to increase the number of available central infusion lines.
SETTING: Cardiovascular intensive care unit where several standard operating procedures (SOPs) dealing with compatibility were already in place.
METHOD: In a prospective intervention study, patients' IV medication was assessed for potential incompatibilities using a database containing compatibility information on approximately 60,000 drug pairs. In a first period, routine administration was monitored in 53 consecutive patients (control group). Then, quality improvement measures were implemented recommending a purging procedure before and after bolus administration of pantoprazole as a drug frequently causing incompatibilities in this setting. Additionally, the use of 4-lumen instead of 3-lumen catheters was suggested whenever considered useful by the responsible physicians. The monitoring was repeated during a second period in another 58 patients consecutively admitted to the same unit (intervention group). MAIN OUTCOME MEASURE: Overall number of patients with at least one incompatible drug pair and number of patients receiving incompatible pantoprazole combinations.
RESULTS: The number of patients receiving incompatible pantoprazole combinations decreased from 15 of the 15 patients receiving pantoprazole (100.0%) in controls to 9/16 (56.2%) in the intervention group (P < 0.01). The overall number of patients with incompatibilities was not influenced by the intervention with 36/58 (62.1%) compared to controls with 38/53 (71.7%, P = 0.28). The fraction of central lines contributed by four lumen central catheters was larger due to the intervention (80/168 lines, 47.6%) compared to controls (16/184, 8.7%, P < 0.001). Only sporadically there were incompatible combinations of drugs governed by the already existing SOPs.
CONCLUSION: In an intensive care setting with good SOP adherence, purging before and after administration decreased the respective incompatibility rate whereas the use of 4-lumen instead of 3- lumen catheters had not the expected benefit on separating drug pairs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20694515     DOI: 10.1007/s11096-010-9422-9

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  34 in total

1.  Evaluation of physicochemical incompatibilities during parenteral drug administration in a paediatric intensive care unit.

Authors:  M Gikic; E R Di Paolo; A Pannatier; J Cotting
Journal:  Pharm World Sci       Date:  2000-06

2.  Adverse drug reactions and drug non-compliance as primary causes of admission to a cardiology department.

Authors:  F Davidsen; T Haghfelt; L F Gram; K Brøsen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Prevention of intravenous drug incompatibilities in an intensive care unit.

Authors:  Thilo Bertsche; Yvonne Mayer; Rebekka Stahl; Torsten Hoppe-Tichy; Jens Encke; Walter Emil Haefeli
Journal:  Am J Health Syst Pharm       Date:  2008-10-01       Impact factor: 2.637

4.  A comprehensive intravenous admixture system.

Authors:  N W Schwartau; E A Schwerman; C O Thompson; K Hauff
Journal:  Am J Hosp Pharm       Date:  1973-07

5.  Medication errors in a nurse-controlled parenteral admixture program.

Authors:  M P Thur; W A Miller; C J Latiolais
Journal:  Am J Hosp Pharm       Date:  1972-04

6.  Incompatibility of labetalol hydrochloride and furosemide.

Authors:  J Zeisler; C Alagna
Journal:  Am J Hosp Pharm       Date:  1993-12

7.  Frequency and clinical outcome of potentially harmful drug metabolic interactions in patients hospitalized on internal and pulmonary medicine wards: focus on warfarin and cisapride.

Authors:  K Laine; J Forsström; P Grönroos; K Irjala; M Kailajärvi; M Scheinin
Journal:  Ther Drug Monit       Date:  2000-10       Impact factor: 3.681

8.  Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.

Authors:  Nariné Baririan; Hugues Chanteux; Eric Viaene; Hélène Servais; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

9.  Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study.

Authors:  Sebastian Schneeweiss; Joerg Hasford; Martin Göttler; Annemarie Hoffmann; Ann-Kathrin Riethling; Jerry Avorn
Journal:  Eur J Clin Pharmacol       Date:  2002-06-12       Impact factor: 2.953

10.  Medication error prevention by clinical pharmacists in two children's hospitals.

Authors:  H L Folli; R L Poole; W E Benitz; J C Russo
Journal:  Pediatrics       Date:  1987-05       Impact factor: 7.124

View more
  4 in total

1.  Safeguarding the process of drug administration with an emphasis on electronic support tools.

Authors:  Hanna M Seidling; Anette Lampert; Kristina Lohmann; Julia T Schiele; Alexander J F Send; Diana Witticke; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

2.  Incompatible intravenous drug combinations and respective physician and nurse knowledge: a study in routine paediatric intensive care.

Authors:  Martina P Neininger; Patricia Buchholz; Roberto Frontini; Wieland Kiess; Werner Siekmeyer; Astrid Bertsche; Manuaela Siekmeyer; Thilo Bertsche
Journal:  Eur J Hosp Pharm       Date:  2017-07-24

Review 3.  Strategies to prevent drug incompatibility during simultaneous multi-drug infusion in intensive care units: a literature review.

Authors:  Laura Négrier; Anthony Martin Mena; Gilles Lebuffe; Pascal Odou; Stéphanie Genay; Bertrand Décaudin
Journal:  Eur J Clin Pharmacol       Date:  2021-03-25       Impact factor: 2.953

4.  Systemic Defenses to Prevent Intravenous Medication Errors in Hospitals: A Systematic Review.

Authors:  Sini Karoliina Kuitunen; Ilona Niittynen; Marja Airaksinen; Anna-Riia Holmström
Journal:  J Patient Saf       Date:  2021-12-01       Impact factor: 2.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.